ACCORD HEALTHCARE LIMITED
Location
Founded
2004-04-13
Risk Signals
337 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Pharmaceutical Preparations, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ACCORD HEALTHCARE LIMITED
Live alerts from global media, monitored by Business Radar
2024-09-24 (thepharmaletter.com)
Hetronifly set to strengthen Accord’s EU injectable oncology portfolio
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of Hetronifly (serplulimab), a recombinant anti-PD-1 monoclonal antibody.
Read more
2022-03-25 (informa.com)
Accord Sees Two Hybrids Endorsed By EU’s CHMP
The latest CHMP meeting has seen the EMA committee issue a positive opinion on two Accord hybrid medicines, Zolsketil (doxorubicin) and Camcevi (leuprorelin), at the same time as SERB’s generic amifampridine tablets were also endorsed.
Read more
2020-10-23 (informa.com)
UK Authorizes Use Of Unlicensed Flu Vaccine
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
Read more
2020-09-22 (informa.com)
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Read more
2020-09-21 (informa.com)
Accord Gets First EU-Wide Nod For Xarelto Rival
Accord Healthcare has garnered the first positive opinion recommending granting a pan-European marketing authorization for a generic version of rivaroxaban from the EMA’s CHMP.
Read more
2020-09-18 (informa.com)
Waylivra Funding Success In England & Germany
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Read more
2020-09-18 (informa.com)
First EMA Nod For Generic Xarelto; Apotex Pulls Upkanz For Neurodegenerative Disease
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023.
Read more